News
LUNG
7.50
+1.35%
0.10
Weekly Report: what happened at LUNG last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at LUNG last week (0408-0412)?
Weekly Report · 04/15 09:08
Weekly Report: what happened at LUNG last week (0401-0405)?
Weekly Report · 04/08 09:09
Pulmonx Corporation's (NASDAQ:LUNG) Share Price Matching Investor Opinion
Pulmonx Corporation (NASDAQ:LUNG) has a price-to-sales ratio of 4.5x. The company's revenue growth is superior to most other medical equipment companies. Pulmonx's P/S ratio is typical of a company expected to perform better than the industry. But there are 3 warning signs to be mindful of for the company.
Simply Wall St · 04/04 11:17
Navigating 6 Analyst Ratings For Pulmonx
Pulmonx Corp is a commercial-stage medical technology company. The company provides a minimally invasive treatment for patients with severe emphysema. Analysts' ratings for Pulmonx vary from bullish to bearish. The average price target is $16.33, with a 12-month target of $17.00.
Benzinga · 04/03 18:00
Piper Sandler Remains a Buy on Pulmonx (LUNG)
TipRanks · 04/03 11:06
Pulmonx Taps Mehul Joshi as Finance Chief
Pulmonx names Mehul Joshi as its permanent finance chief. Joshi has more than 30 years of experience in finance. He succeeds interim CFO John McKune. Pulmonx is a developer of minimally invasive treatments for lung disease. He most recently served as CFO of PhenomeX.
Dow Jones · 04/02 20:58
Pulmonx Welcomes Mehul Joshi as New CFO with Comprehensive Compensation Package
TipRanks · 04/02 20:23
Pulmonx appoints Mehul Joshi as CFO
Healthcare Pulmonx appoints Mehul Joshi as CFO effective April 3, 2024. Joshi succeeds John McKune, who has served as interim CFO since October 10, 2023. Most recently, Joshi served as the CFO of PhenomeX.
Seeking Alpha · 04/02 20:10
Pulmonx Announces Appointment Of Mehul Joshi As Chief Financial Officer, Effective April 3, 2024
Mehul Joshi will succeed John McKune as Chief Financial Officer of Pulmonx Corporation. Joshi brings over 30 years of experience in finance, accounting and strategic planning. He succeeds McKune, who will transition to his prior role as Vice President, Corporate Controller. The Company is a global leader in minimally invasive treatments for lung disease.
Benzinga · 04/02 20:09
*Pulmonx: Announces Appointment of Mehul Joshi as Chief Fincl Officer >LUNG
Dow Jones · 04/02 20:06
PULMONX CORP - APPOINTMENT OF MEHUL JOSHI AS CHIEF FINANCIAL OFFICER, EFFECTIVE APRIL 3, 2024
Reuters · 04/02 20:05
Press Release: Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
Pulmonx Corporation appoints Mehul Joshi as Chief Financial Officer, effective April 3, 2024. Joshi brings over 30 years of experience in finance, accounting and strategic planning. He succeeds John McKune, who has served as the Company's interim chief financial officer. Pulmonx is a global leader in minimally invasive treatments for lung disease.
Dow Jones · 04/02 20:05
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
Pulmonx Corporation appoints Mehul Joshi as Chief Financial Officer, effective April 3, 2024. Joshi succeeds John McKune. Pulmonx is a global leader in minimally invasive treatments for lung disease. The Company is headquartered in San Francisco, California.
Barchart · 04/02 15:05
Weekly Report: what happened at LUNG last week (0325-0329)?
Weekly Report · 04/01 09:08
Pulmonx: Revisiting Thesis Following Management Change
Pulmonx Corporation's shares have performed poorly over the past year, returning -16%. The company's CEO recently announced his retirement, raising questions about potential changes in corporate strategy. Pulmonx is a medical device company developing a treatment for patients with severe emphysema. In my opinion, the market for endobronchial valves is much smaller than anticipated. I reduced my rating on PulmonX Corporation to a sell a year ago.
Seeking Alpha · 03/26 09:38
Weekly Report: what happened at LUNG last week (0318-0322)?
Weekly Report · 03/25 09:08
Weekly Report: what happened at LUNG last week (0311-0315)?
Weekly Report · 03/18 09:08
Weekly Report: what happened at LUNG last week (0304-0308)?
Weekly Report · 03/11 09:08
Weekly Report: what happened at LUNG last week (0226-0301)?
Weekly Report · 03/04 09:08
More
Webull provides a variety of real-time LUNG stock news. You can receive the latest news about Pulmonx Corp through multiple platforms. This information may help you make smarter investment decisions.
About LUNG
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.